CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Dapagliflozin for treating chronic heart failure with reduced ejection fraction Association of Cardiovascular Disease With Respiratory Disease Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association

Research CorrespondenceVolume 7, Issue 3, March 2019

JOURNAL:JACC: Heart Failure Article Link

Primary Prevention of Heart Failure in Women

MA Daubert, PS Douglas. Keywords: heart failure; prevention; women

ABSTRACT


The incidence of heart failure (HF) is increasing, particularly among women, and constitutes a rapidly growing public health problem. The primary prevention of HF in women should involve targeted, sex-specific strategies to increase awareness, promote a heart healthy lifestyle, and improve treatments that optimally control the risk factors for HF with reduced ejection fraction and HF with preserved ejection fraction. Epidemiological and pathophysiological differences in both HF subtypes strongly suggest that sex-specific preventive strategies and risk factor reduction may be particularly beneficial. However, significant gaps in sex-specific knowledge exist and are impeding preventive efforts. To overcome these limitations, women need to be adequately represented in HF research, sex differences must be prospectively investigated, and effective sex-specific interventions should be incorporated into clinical practice guidelines. This review summarizes the existing evidence that supports the primary prevention of HF in women and identifies potential strategies that are most likely to be effective in reducing the burden of HF among women.